An observational study in Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2020-03-20.
Sponsored by Bristol-Myers Squibb · Observational
This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 264 is above the median of 155 across 1,057 observational studies indexed under Arthritis.
Browse Arthritis studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will include all patients with JIA who are treated with abatacept
Exclusion Criteria:
Other: Non-Interventional
Non-Interventional
Incidence of infections
Time frame: 110 months
Incidence of malignancies
Time frame: 110 months
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb